World-first trial to test whether Alzheimer’s drug can delay or prevent disease

• Surrey and Borders Partnership NHS Foundation Trust has become the first site in Europe to join an international trial for a prospective Alzheimer's drug.
• The trial will recruit 1,600 healthy adults aged between 55 and 80 to test whether the drug Trontinemab can delay or prevent the onset of Alzheimer's disease.
• UK participants will be screened for memory loss and given a blood test to check for the p-tau217 biomarker before receiving the treatment.
• Developed by Roche, Trontinemab is delivered intravenously and targets harmful amyloid plaques that damage brain cell function.
• Chief investigator Professor Ramin Nilforooshan highlighted that the study shifts research focus towards intervening before symptoms appear.

IN FULL

Alzheimer’s drug to be offered to people without symptoms in bid to prevent onset of disease